Daxor Corporation (NASDAQ:DXR) Short Interest Down 66.2% in June

Daxor Corporation (NASDAQ:DXR) was the target of a large decrease in short interest in June. As of June 15th, there was short interest totaling 2,083 shares, a decrease of 66.2% from the May 31st total of 6,164 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average trading volume of 2,060 shares, the short-interest ratio is presently 1.0 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Aristides Capital LLC bought a new position in shares of Daxor in the 1st quarter worth $403,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in Daxor during the first quarter valued at about $245,000. Nano Cap New Millennium Growth Fund L P purchased a new position in Daxor in the fourth quarter valued at about $184,000. Crescent Grove Advisors LLC purchased a new position in Daxor in the first quarter valued at about $104,000. Finally, Osaic Holdings Inc. bought a new position in Daxor in the second quarter worth about $86,000. 1.34% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Daxor in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

Daxor Trading Up 0.2%

NASDAQ DXR traded up $0.02 during trading on Tuesday, reaching $10.13. 3,759 shares of the company’s stock traded hands, compared to its average volume of 8,301. The company’s 50 day simple moving average is $10.35 and its two-hundred day simple moving average is $11.45. Daxor has a 12-month low of $8.56 and a 12-month high of $14.76.

Daxor (NASDAQ:DXR) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.10) earnings per share for the quarter.

About Daxor

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA?100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA?100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.